Creative Biolabs is committed to developing microfluidic and lab-on-a-chip systems for biomedical applications, providing comprehensive design and customization services for multidrug resistance (MDR) testing of antibacterial and chemotherapeutic drugs.
Generally speaking, MDR is a kind of resistance of microorganism to at least one of three or more antimicrobial categories. Infectious diseases caused by MDR bacteria are threatening global health. In cancer, MDR is a phenomenon that tumor cells have a wide range of drug resistance to a variety of compounds unrelated to their structure and function. It is one of the main challenges in cancer treatment, which occurs in a short period of time during/after treatment. MDR may be caused by a variety of mechanisms, which will eventually lead to cancer recurrence and death in 90% of patients.
Fig.1 Cellular drug resistance mechanisms. (Hamed, 2019)
Because the delay in the identification of MDR significantly increases mortality, rapid and accurate antibiotic sensitivity test (AST) or MDR detection in the early stage of cancer is crucial. Early detection of MDR can reduce the treatment time, thereby reducing related costs and significantly increasing the success rate of treatment. In recent decades, microfluidic technology has developed rapidly and has provided many applications in life science. Such a platform provides new insights into biological processes and can generate new drug analysis efficiently and quickly.
At present, Creative Biolabs provides the design, development and customization services of MDR rapid detection system based on microfluidic technology. In AST, the application of the microfluidic system makes it possible to carry out antibiotic susceptibility test on a single cell level, which provides a broad prospect for rapid and accurate determination of antimicrobial susceptibility spectrum to guide antibiotic treatment decisions. Similarly, the in vitro model developed by microfluidic technology can more reliably predict the efficacy, toxicity and pharmacokinetics of drug compounds in the human body, which also brings good news for the detection of MDR in early cancer.
Fig.2 Example: microfluidic technologies for rapid antibiotic susceptibility tests (ASTs) at the single-cell level. (Zhang, 2020)
We also provide consulting and manufacturing services on microfluidics for companies and institutions. If you have any special needs in our MDR detection systems development services, please feel free to contact us for more details.
For Research Use Only. Not For Clinical Use.